|Acarbose Cardiovascular Evaluation|
The Acarbose Cardiovascular Evaluation (ACE) trial is a double-blind, randomised, multi-centre, cardiovascular intervention study coordinated by the University of Oxford Diabetes Trials Unit (DTU). It has been designed by Professors Rury Holman (Oxford University, UK), Hu Dayi (People's Hospital Peking University, China) and Pan Chang Yu (Chinese PLA General Hospital, Beijing, China).
ACE commenced in 2009 and is being conducted in around 150 Hospitals in mainland China and Hong Kong. The trial aims to determine whether reducing post prandial glycaemia with acarbose can reduce cardiovascular-related mobidity and mortality in patients with established cardiovascular disease (CVD) or accute coronary syndrome (ACS) who also have impaired glucose intolerance (IGT). Patients will be followed up until a minimum of 904 adjudicated primary events are achieved, with the results expected in 2018.
You can apply to be a clinical centre using this form.
The ACE study is funded by Bayer HealthCare in an academic collaboration with the Diabetes Trials Unit.